In a phase 3 clinical study evaluating the long-term safety and efficacy of eltrombopag in adults with ITP [24], the major adverse effects reported with the TPO-RA were liver function disorder (15%; 45/302), a thromboembolic event (6%; 19/302), included such as deep vein thrombosis, pulmonary embolism, and myocardial or cerebral infarctions. Here, TPO is linked to cerebral infarction.